维普中文期刊产品整合服务
207篇 您的检索式:作者名="DOUGLAS SA"
    题名 作者 年代 出处 被引量
1Expression of urotensin-Ⅱ in human coronary atherosclerosis显示文摘Hassan GS Douglas SA Ohlstein EH 2005Peptide2005,26,12:1
2A retrospective comparision of endonasal KTP laser dacryocystorhinostomy versus external dacryocystorhinostomy显示文摘Mirza S A Barmani A Douglas SA 2002Clin Otolaryngol2002,27,:1
3Localization of urotensin-Ⅱ immunoreactivity in normal human kidneys and renal carcinoma显示文摘Shenouda A Douglas SA Ohlstein EH 2002J Histochem Cytochem2002,50,7:1
4Localization of urotensin -Ⅱ immunoreactivity in normal human kidneys and renal carcinoma 显示文摘Shenouda A Douglas SA Ohlstein EH 2002J Histochem Cytochem2002,50,7:1
5Human urotensin Ⅱ,the most potent mammalian vasoconstrictor identified to date,as a therapeutic target for the management of cardiovascular disease显示文摘 Ohlstein EH 2000Trends Cardiovasc Med2000,10,:1
6Molecular and pharmacological characterization of genes encoding urotensin Ⅱ peptides and their cognate G-protein coupled receptors from the mouse and monkey显示文摘Elshourbagy NA Douglas SA Aiyar NV 2002Br J Pharmacol2002,136,1:1
7Human urotensin II,the most potent mammalian vasoconstrictor identified to date,as a therapeutic target for the management of cardiovascular disease显示文摘Douglas SA Ohlstein EH 2000Trends Cardiovasc Med2000,10,:1
8Potent vasodilator responses to human urotemin- Ⅱ in human pulmonary and abdominal resistance arteries 显示文摘Stirrat A Gallagher M Douglas SA 2001Am J Physiol Heart Circ Physiol2001,280,2:1
9Differential vasoconstrictor activity of human urotensin Ⅱ in vascular tissue isolated from the rat, mouse, dog, pig,marmoset and cynomolgus monkey显示文摘Douglas SA Sulpizio AC Piercy V 2000Br J Pharmacol2000,131,:1
10Human urotensin Ⅱ is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate显示文摘 Ashton DJ Sauermelch CF 2000J Cardiovasc Pharmacol2000,36,5:1
11Human urotensin-II,the most potent mammalian vasoconstrictor identified to date,as a therapeutic target for the management of cardiovascular disease显示文摘Douglas SA Ohlstein EH 2000Trends Cardiovasc Med2000,10,6:1
12Increased expression of urotensin Ⅱ and its cognate receptor GPR14 in atherosclerotic lesions of the human aorta显示文摘Bousette N Patel L Douglas SA 2004Atherosclerosis2004,176,:1
13Differential vasoeonstrtor activity of human urotensin Ⅱ in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and eynomolgus monkey显示文摘DOUGLAS SA SULPIZIO AC PIERAY V 2000Br J Pharmacol2000,131,7:1
14Differential vasoconstrictor activity of human urotensin-Ⅱ in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey 显示文摘 Sulpizio AC Piercy V 2000Br J Pharmacol2000,131,7:1
15Molecular and pharmacological characterization of genes encoding urotensin Ⅱ peptides and their cognate G-protein-coupled receptors from the mouse and monkey 显示文摘Elshourbagy NA Douglas SA Shabon U 2002Br J Pharmacol2002,136,1:1
16Human Urotensin-Ⅱ,the most potent mammalian vasoconstrictor identified to date,as a therapeutic target for the manegement of cardiovascular disease显示文摘Douglas SA Ohlestein EH 2000Trends Cardiovasc Med2000,10,6:1
17comparisision of endonasal KTP laser dacryocystorhinostomy versus external dacryocyastorhinostomy显示文摘Mirza S AL Barrnani A Douglas SA Aretrosective 2002Cli Okikarybgol2002,27,:1
18Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury显示文摘Ohlstein EH Douglas SA Sung CP 1993Proc Natl Acad Sci USA1993,90,13:1
19Behavioral interventions for tie disorders 显示文摘Franklin SA Michael RW Douglas WW 2010Psyehiatr Clin North Am2010,33,3:1
20Localizadon of urotcnsin Ⅱ immunoreactivity in normal human kidneys and renal carcinoma显示文摘Shenouda A Douglas SA Ohlstein EH 2002J Histochem Cytochem2002,50,7:1
返回顶部 每页显示:
共11页 首页 上一页 第1页 下一页 末页 /11 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费